Key Points
- Privia Health Group CFO David Mountcastle sold 21,275 shares on July 9 at an average price of $27.67, totaling about $588,679. The sale was made under a pre-arranged Rule 10b5-1 trading plan and reduced his ownership by 11.43%.
- Mountcastle has been actively selling shares recently, including additional sales on July 7 and July 2, as well as several transactions in late June and May. These trades suggest a pattern of ongoing insider selling rather than a one-time move.
- PRVA shares were trading near their 12-month high, opening at $27.89 versus a 12-month range of $18.77 to $27.96. Analysts remain broadly positive overall, with a consensus rating of Moderate Buy and an average target price of $31.15.
Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) CFO David Mountcastle sold 21,275 shares of the company's stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $27.67, for a total transaction of $588,679.25. Following the completion of the transaction, the chief financial officer owned 164,853 shares of the company's stock, valued at approximately $4,561,482.51. This trade represents a 11.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Mountcastle also recently made the following trade(s):
- On Tuesday, July 7th, David Mountcastle sold 600 shares of Privia Health Group stock. The stock was sold at an average price of $27.57, for a total transaction of $16,542.00.
- On Thursday, July 2nd, David Mountcastle sold 24,734 shares of Privia Health Group stock. The stock was sold at an average price of $27.50, for a total transaction of $680,185.00.
- On Friday, June 26th, David Mountcastle sold 17,196 shares of Privia Health Group stock. The shares were sold at an average price of $25.18, for a total value of $432,995.28.
- On Monday, May 11th, David Mountcastle sold 3,385 shares of Privia Health Group stock. The shares were sold at an average price of $22.60, for a total value of $76,501.00.
- On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total value of $30,150.00.
- On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The stock was sold at an average price of $25.03, for a total value of $179,690.37.
Privia Health Group Trading Up 1.5%
NASDAQ PRVA opened at $27.89 on Tuesday. The business's 50-day moving average price is $23.82 and its two-hundred day moving average price is $23.17. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $27.96. The firm has a market capitalization of $3.51 billion, a PE ratio of 174.32, a price-to-earnings-growth ratio of 2.17 and a beta of 0.83.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on PRVA. Evercore set a $26.00 price objective on Privia Health Group in a research note on Wednesday, April 8th. Canaccord Genuity Group decreased their target price on shares of Privia Health Group from $35.00 to $34.00 and set a "buy" rating for the company in a research report on Friday, May 8th. Barclays lowered their price target on shares of Privia Health Group from $25.00 to $24.00 and set an "equal weight" rating for the company in a report on Tuesday, May 26th. Weiss Ratings upgraded shares of Privia Health Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, July 2nd. Finally, Zacks Research downgraded shares of Privia Health Group from a "hold" rating to a "strong sell" rating in a research report on Tuesday, July 7th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.15.
Get Our Latest Stock Analysis on PRVA
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in PRVA. Bayban acquired a new position in shares of Privia Health Group in the 4th quarter valued at about $26,000. Hantz Financial Services Inc. grew its stake in Privia Health Group by 456.2% during the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company's stock worth $27,000 after purchasing an additional 926 shares during the period. Global Retirement Partners LLC grew its stake in Privia Health Group by 579.8% during the fourth quarter. Global Retirement Partners LLC now owns 1,584 shares of the company's stock worth $38,000 after purchasing an additional 1,351 shares during the period. Harbor Investment Advisory LLC bought a new stake in Privia Health Group in the second quarter worth approximately $69,000. Finally, Canada Pension Plan Investment Board increased its holdings in Privia Health Group by 48.0% in the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company's stock worth $85,000 after purchasing an additional 1,200 shares in the last quarter. 94.48% of the stock is owned by institutional investors.
Privia Health Group Company Profile
(
Get Free Report)
Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.
Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
